OOIR: Observatory of International Research

Papers

(The TQCC of Leukemia Research is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Acquired alpha thalassemia associated with myeloid malignancy: A systematic literature review	52
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database	31
Editorial Board	28
Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy	27
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study	26
MDS AND AUTO-IMMUNITY	23
DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY SINGLE-CELL MULTI-OMICS SEQUENCING	21
CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES	20
Topic: AS01-Diagnosis/AS01a-Cytomorphology: ARTIFICIAL INTELLIGENCE MAY HELP THE HEMATOPATHOLOGIST IN EVALUATION OF BONE MASS AND CELLULARITY IN BONE MARROW SPECIMENS OF PATIENTS WITH MDS	19
5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES	19
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: DER(1;7)(Q10;P10) DEFINES A DISTINCT SUBTYPE OF MYELODYSPLASIA	18
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: HIGHER LEPTIN LEVEL IS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME: A COMPARATIVE STUDY	17
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES TH	16
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)	15
Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia	15
ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT	14
Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis	14
Editorial Board	13
DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma	12
SOX11 AND EPSTEIN–BARR VIRUS MAY SUBSTITUTE EACH OTHER IN EARLY PATHOGENESIS OF BURKITT LYMPHOMA	12
EFFICACY AND SAFETY OF SEQUENTIAL DIFFERENT B CELL ANTIGEN-TARGETED CAR T-CELL THERAPY FOR PEDIATRIC REFRACTORY/ RELAPSED BURKITT LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT	12
TARGETED THERAPY INCREASES PD-L1 PROTEIN EXPRESSION IN CELL LINES OF MEDIASTINAL LYMPHOMA	12
Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)	12
Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis	11
Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment	11

Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling	11
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION	11
Treatment of lymphomas via regulating the Signal transduction pathways by natural therapeutic approaches: A review	11
Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis	11
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group	11
How low can you go?: Methodologic considerations in clonal hematopoiesis variant calling	11
Topic: AS01-Diagnosis/AS01a-Cytomorphology	11
Changing frontline AML treatment patterns from 2013 to 2022	11
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia	11
ACCELERATED RNA SPLICING DYNAMICS DURING ERYTHROID DIFFERENTIATION AMPLIFY MIS-SPLICING IN SF3B1-MUTANT MDS-RS	11
Presentation name: Supportive Care	10
Editorial Board	10
IMPACT OF RITUXIMAB ON IMMUNE STATUS FOLLOWING THERAPY IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN LYMPHOMA: RESULTS OF THE INTER-B-NHL RITUX 2010 TRIAL	10
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents	10
Poster Pitch Presentations	10
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment	10
Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III	10
ALK+ ALCL EVADES IMMUNE SURVEILLANCE THROUGH NPM-ALK-DRIVEN EPIGENETIC REPRESSION OF Cd48	10
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis	9
FULMINANT, EBV DRIVEN PLASMACYTIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) WITH LOSS OF 1P AND GAIN OF TP53/CEP17 AND IGH BONE MARROW INVOLVEMENT AFTER LIVER TRANSPLANT IN 17-MONTH OLD BOY	9
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCREASED DNA-CELL-CYCLE S-PHASE FRACTION IS RELATED TO INCREASED INCIDENCES OF IMMATURE MYELOID CELLS AND HIGH IPSS-R RI	9
PRE-TRANSPLANT TREATMENT OF HEPATISPLENIC T-CELL LYMPHOMA (GAMMA-DELATA): A PEDIATRIC CASE REPORT	9
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) P	9
Topic: AS09-Quality of life-Disease experiences: ANEMIA OF CHRONIC DISEASE IN THE ELDERLY: EVALUATION OF HEPCIDIN EXPRESSION AND ITS RELATIONSHIP WITH PROINFLAMMATORY CYTOKINES AND CLINICAL AND LABORA	9
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting	8
Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia	8
FDG-PET/CT IMAGING IN PEDIATRIC PRECURSOR B-CELL LYMPHOBLASTIC LYMPHOMA (BCP-LBL) SHOWS BONE (MARROW) INVOLVEMENT IN A VAST MAJORITY OF PATIENTS	8
Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia	8
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation	8
Roles of noncoding RNAs in multiple myeloma	8
CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells	8
A RARE CASE OF PRIMARY OCULAR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN A BRAZILIAN CHILD	8
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis	8
Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study	8
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy	8
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies	8
Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT	8
MCL-1 INHIBITORS INDUCES APOPTOSIS IN VITRO IN BURKITT LYMPHOMA CELL LINES AND INHIBITS IN VIVO BURKITT LYMPHOMA PROGRESSION	8
Cost-effectiveness of blinatumomab for the treatment of B‑precursor acute lymphoblastic leukemia pediatric patients with high‑risk first‑relapse in Mexico	8
A machine learning approach to predicting risk of myelodysplastic syndrome	8
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML	7
LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma	7
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: PREVALENCE, DYNAMICS AND CLINICAL SIGNIFICANCE OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN NEWLY DIAGNOSED CANCER PATIEN	7
Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture	7
Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing	7
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols	7
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: SECONDARY FINDINGS IN EXOME SEQUENCING IN 240 EARLY-ONSET ADULT MYELODYSPLASTIC SYNDROMES WITHOUT PREVIO	7
CURRENT CARDIOVASCULAR DISEASE (CVD) RISK PREDICTION MODELS ARE NOT APPLICABLE IN MDS PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE OBSERVATIONAL SINGLE-CENTRE COHORT STUDY	7
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues	7
MiR-409–3p regulates the proliferation and apoptosis of THP-1 through targeting Rab10	7

Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: INTEGRATED ANALYSIS OF MDS-OMICS INFORMS ON DRUG RESPONSE PROFILES	7
PYRIMETHAMINE, A STAT3 INHIBITOR, HAS SYNERGY WITH VENETOCLAX AND IS EFFICACIOUS IN HYPOMETHYLATING AGENT RESISTANT MDS/AML	7
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity	6
BCL2 FAMILY INHIBITORS	6
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation	6
Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL	6
Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement	6
Corrigendum to “Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy” [Leuk. Res. 122 (2022) 106949]	6
VARIANT ALK-FUSION POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): A POPULATION-BASED COHORT OF THE NHL-BFM STUDY GROUP	6
Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia	6
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia	6
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN LOWER-RISK MDS TRANSFUSION-DEPENDENT PATIENTS; A SINGLE-CENTRE EXPERIENCE	6
THE CHALLENGE OF PROSPECTIVE DISTINCTION BETWEEN NON-NEOPLASTIC VERUS NEOPLASTIC EBV-ASSOCIATED HLH	6
18F-FDG-PET/CT IN THE ASSESSMENT OF BONE MARROW INVOLVEMENT IN PEDIATRIC NON-HODGKIN LYMPHOMA- A SINGLE CENTER EXPEREIENCE	6
Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines	6
Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience	6
Impact of the quantity and quality of the skeletal muscle on survival among patients undergoing allogeneic hematopoietic stem cell transplantation	6
Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia	6
Topic: AS01-Diagnosis/AS01b-Flow cytometry: IMMUNOPHENOTYPIC BONE MARROW CHARACTERISTICS IN MYELODYPLASTIC SYNDROME WITH SF3B1 MUTATION	6
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study	6
BONE MARROW INFILTRATION AS A PROGNOSTICE FACTOR IN PEDIATARIC BURKITT LYMPHOMA PATIENTS	6
PEDIATRIC LOW GRADE LYMPHOMAS: A REPORT FROM A SINGLE CENTRE	6
PRINCIPAL ACTIONS OF THE MYELODYSPLASTIC SYNDROME HSCT AMERICAN LATIN REGISTRY	6
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience	6
Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvem	6
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation	6
Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms	6
Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series	6
Editorial Board	6
Topic: AS01-Diagnosis/AS01a-Cytomorphology: DIAGNOSTIC CHALLENGE BETWEEN WHO AND ICC CLASSIFICATION	6
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: MUTATION-SPECIFIC HSPC ENRICHMENT PATTERNS UNDERLIE PROGNOSTICALLY SIGNIFICANT TRANSCRIPTOMIC SUBGROUPS OF MDS PATIENTS	6
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation – Post-transplantation treatment: IN VIVO DUAL T CELL DEPLETION (TCD) IMPROVES TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME	5
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS	5
SEARCHING FOR THE CAUSES OF ANAPLASTIC LARGE CELL LYMPHOMA	5
Retraction notice to “Low-dose radiotherapy (2×2 g) versus low doses and rituximab in the treatment of marginal zone b-cell lymphoma previously untreated” [Leuk. Res. 98C (2020) 106443]	5
LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia	5
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche	5
Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study	5
E-Poster Viewing	5
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITID	5
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123	5
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation - Bridging to transplantation	5
IMMUNOGLOBULIN SUBCLASSES OF ANTI-ALK ANTIBODIES IN PEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA	5
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study	5
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias	5
Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei	5
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling	5
A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?	5
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT FOR PATIENTS WITH LOWER RISK MDS ADMITTED TO THE HEMATOLOGY DEPARTMENT OF THE COLENTINA CLINICAL HOSPITAL - DATA FR	5
Philadelphia-positive B-lymphoblastic leukemia in a middle-income country – A real-world multicenter cohort	5
QOL	5
PI3K/AKT inhibitor BEZ-235 targets CCND2 and induces G1 arrest in breast implant-associated anaplastic large cell lymphoma	5
Universal posttransplant cyclophosphamide after allogeneic transplant, a retrospective single institution study	5
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation	5
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment	5
Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: VENETOCLAX AND AZACYTIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES, A REAL-WORLD EXPERIENCE. LATIN-AMERICAN MDS GROUP – GLAM	5
Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study	4
Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy	4
MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12	4
PDGFRβ DRIVES PROGRESSION BY ONCOGENE TRANSCRIPTION THROUGH STAT3/STAT5 HYPERACTIVATION IN ALCL	4
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche	4
CHARACTERIZING THROMBOSIS IN CHILDREN & ADOLESCENTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA	4
RITUXIMAB CLEARANCE IN PEDIATRIC PATIENTS WITH MAATURE B-CELL NON-HODGKIN LYMPHOMA	4
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia	4
Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL)	4
Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma	4
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: BEYOND DDX41: DDH AND DHX HELICASES ARE MUTATED IN MDS	4
Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy	4
Growth and dormancy control of myeloma cells by mesenchymal stem cells	4
Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma	4
Multiple cells of origin in common with various types of mouse N-Myc acute leukemia	4
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche	4
ALK INIHIBITOR THERAPY IN ALCL	4
VARYING OUTCOMES OF MATURE T AND NK LYMPHOMA IN PEDIATRIC AND ADOLESCENT/YOUNG ADULT PATIENTS: A SINGLE INSTITUTION EXPERIENCE	4
Therapeutic advances for the management of adult T cell leukemia: Where do we stand?	4
NAP1L5 promotes epithelial–mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia	4
Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era	4
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE	4
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB	4
Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients	4

Editorial Board	4
Proposal and clinical application of molecular genetic risk scoring system, “MRplus”, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre	4
Alternative polyadenylation quantitative trait loci contribute to acute myeloid leukemia risk genes regulation	4
PEDIATRIC AND YOUNG ADULT ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA GENETICALLY DIFFERS FROM THE ADULT COUNTERPART	4
Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions	4
Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review	4
Topic: AS01-Diagnosis/AS01b-Flow cytometry: COMMITTED AND IMMATURE ERYTHROID PROGENITORS ARE DIFFERENTLY DISTRIBUTED IN LOWER RISK MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO CATEGORY AND CORRELATE WIT	4
Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML),	4
Corrigendum to “The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement” [Leukemia Res. 100 (2021) 106480]	4
Erratum to ‘Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system’ [Leukemia Research 112C	4
Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT)	4
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPEN	4
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine	3
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN THE TREATMENT OF MDS PATIENTS. A SINGLE CENTER EXPERIENCE	3
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents	3
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ROUTINE INFLAMMATORY MARKERS ARE ELEVATED IN MYELODYSPLASTIC SYNDROMES AT PRESENTATION	3
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation	3
Presentation name: What we learn from real-world registries	3
AN UNUSUAL PRESENTATION OF A RARE PEDIATRIC DISEASE	3
Topic: AS01-Diagnosis/AS01a-Cytomorphology: AUTOMATED DIGITAL TOOL FOR MDS AND MDS/MPN CLASSIFICATION USING WHO AND ICC: INTERNATIONAL GUIDELINES WORKING GROUP ON MDS DIAGNOSIS, PROGNOSIS, AND GERMLIN	3
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): MUTATIONS OF SF3B1 GENE AND ITS SIGNIFICANCE ON PATIENTS WITH MYELODYSPASTIC SYNDROMES (MDS)	3
Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort	3
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria	3
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)	3
Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution	3
Topic: AS01-Diagnosis/AS01a-Cytomorphology: NON-INVASIVE WEB-BASED DIAGNOSTIC ALGORITHM FOR MDS – MODEL PERFORMANCE AND VALIDATION	3
Clonal hematopoiesis: Molecular and clinical implications	3
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution	3
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion	3
The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis	3
Editorial Board	3
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE	3
Topic: AS08-Treatment/AS08k-Supportive care - Transfusion medicine and MDS	3
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation	3
Editorial Board	3
BCR EXPRESSION IN BURKITT LYMPHOMA: NEW INSIGHT IN MUTATIONAL LANDSCAPE	3
PEDIATRIC INFRADIAPHRAGMATIC HODGKIN’S LYMPHOMA: A UNIQUE IDENTITY	3
MOLECULAR GENETICS ANALYSIS OF B-CELL PRECURSOR LYMPHOMA IN PEDIATRIC AND ADOLESCENT PATIENTS REVEALS HIGH FREQUENCY OF KMT2A TRANSLOCATIONS	3
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): MAMMALIAN DIAPHANOUS-RELATED FORMIN 1 IS REQUIRED FOR MAINTAINING HEMATOPOIETIC STEM CELL QUIESCENCE AND SURVIVAL VIA REGU	3
Central nervous system involvement in adult acute myeloid leukemia patients	3
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas	3
Single vs double umbilical cord blood transplantation in acute leukemia: Systematic review and meta-analysis	3
EPSTEIN-BARR VIRUS ORCHESTRATE THE TUMOR MICROENVIRONMENT OF BURKITT LYMPHOMA	3
A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis	3
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial	3
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation	3
Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms	3
CLINICAL SPECTRUM OF PRECURSOR B-CELL LYMPHOBLASTIC MALIGNANCIES: A LARGE COHORT STUDY OF 364 PEDIATRIC PATIENTS	3
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia	3
Presentation name: TGFbeta pathway targeting	3
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations	3
Effects of conventional interventions on early-stage primary cutaneous marginal zone lymphoma: A population-based study	3
Editorial Board	3
Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?	3
Sparsity regularization enhances gene selection and leukemia subtype classification via logistic regression	3
The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study	3
The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia	3
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience	3
Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models	3
Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy	3
25-Hydroxy vitamin D deficiency predicts inferior prognosis in Hodgkin lymphoma	2
Blood cancer therapy with synthetic receptors and CRISPR technology	2
Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia	2
GERMLINE DDX41 MUTATIONS : CLINICAL IMPACT & ETHNIC DIVERSITY	2
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment	2
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy	2
CURRENT STATUS OF MOLECULAR ANALYSIS OF MRD IN MDS	2
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation	2
Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation	2
Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation—An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap	2
Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest	2
BCR-ABL is enriched in S- and G2-cell cycle phases	2
Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care	2
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience	2
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax	2
Effects of neuromuscular electrical stimulation combined with resistance exercises on muscle strength in adult hematological cancer patients: A randomized controlled study	2
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia	2
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS	2
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells	2
Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression	2
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines	2
ADOLESCENT AGE AT DIAGNOSIS MAY NEGATIVELY IMPACT CLINICAL OUTCOMES IN PEDIATRIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER	2
Patient-centric care in myelodysplastic syndromes: A global systematic literature review and gap analysis	2
Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5	2
Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis	2
Gene regulatory mechanisms of T cell exhaustion in diffuse large B cell lymphoma based on single-cell transcriptome data	2
A UK POPULATION-BASED STUDY OF NON-HODGKIN LYMPHOMA IN ADOLESCENTS AND YOUNG ADULTS: TREATMENT-RELATED OUTCOMES FOR DIFFUSE LAREG B-CELL	2
Invited Speakers	2
Topic: AS08-Treatment/AS08i-observational studies: ALLOGENEIC ADOPTIVE CELLULAR IMMUNOTHERAPY FOR MYELODYSPLASTIC SYNDROME AND ITS EFFECT ON TRISOMY OF CHROMOSOME 8	2
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): CORRECTING DYSREGULATED IRON METABOLISM IN A MURINE MODEL OF MDS	2
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution	2
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: THE IMPACT OF CHIP ON CHEMOTHERAPY-RELATED OUTCOMES AND CLONAL DYNAMICS IN OLDER LYMPHOMA PATIENTS	2
The relationship between clinical prognostic factors, microvascular density, and tumor-infiltrating lymphocytes with CD47 and SIRPα expression in diffuse large B cell lymphomas	2
Editorial Board	2
Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients	2